{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:38:46Z","timestamp":1761183526677,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.dmpk.2016.11.004","type":"journal-article","created":{"date-parts":[[2016,11,23]],"date-time":"2016-11-23T03:23:34Z","timestamp":1479871414000},"page":"69-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Increase in the systemic exposure of primary metabolites of Midazolam in rat arising from CYP inhibition or hepatic dysfunction"],"prefix":"10.1016","volume":"32","author":[{"given":"Tsubasa","family":"Hasegawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satomi","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4867-9361","authenticated-orcid":false,"given":"Keiko","family":"Minami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruki","family":"Higashino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihisa","family":"Shitara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dmpk.2016.11.004_bib1","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1039\/b812777h","article-title":"A\u00a0convenient chemo-enzymatic and 18F-labelling of both enantiomers of trans-1-toluenesulfonyloxymethyl-2-fluoromethly-cyclopropane","volume":"6","author":"Riss","year":"2008","journal-title":"Org Biomol Chem"},{"key":"10.1016\/j.dmpk.2016.11.004_bib2","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/S0140-6736(00)04960-6","article-title":"Lessons from the glitazones: a story of drug development","volume":"357","author":"Gale","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.dmpk.2016.11.004_bib3","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0002-9343(02)01529-2","article-title":"Troglitazone-induced liver failure: a case study","volume":"114","author":"Graham","year":"2003","journal-title":"Am J Med"},{"key":"10.1016\/j.dmpk.2016.11.004_bib4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2133\/dmpk.21.347","article-title":"Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review","volume":"21","author":"Masubuchi","year":"2006","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.dmpk.2016.11.004_bib5","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1056\/NEJM199803263381314","article-title":"Hepatic dysfunction associated with troglitazone","volume":"338","author":"Watkins","year":"1998","journal-title":"N\u00a0Engl Med"},{"key":"10.1016\/j.dmpk.2016.11.004_bib6","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/B978-0-12-374194-3.00033-0","article-title":"Biotransformations leading to toxic metabolites: chemical aspect","author":"Macherey","year":"2008","journal-title":"Pract Med Chem"},{"key":"10.1016\/j.dmpk.2016.11.004_bib7","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1124\/dmd.108.020545","article-title":"Comparison of the bioactivation potential of the antidepressant and hepatotoxin nefazodone with aripiprazole, a structural analog and marketed drug","volume":"36","author":"Bauman","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2016.11.004_bib8","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/sj.tpj.6500210","article-title":"Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes","volume":"3","author":"Ho","year":"2003","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.dmpk.2016.11.004_bib9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0920-1211(02)00188-2","article-title":"Carbamazepine and oxcarbazepine decrease phenytoin metabolism through inhibition of CYP2C19","volume":"52","author":"Lakehal","year":"2002","journal-title":"Epilepsy Res"},{"year":"2008","series-title":"Guidance for Industry: safety testing of drug metabolites","author":"Center for Drug Evaluation and Research (CDER)","key":"10.1016\/j.dmpk.2016.11.004_bib10"},{"key":"10.1016\/j.dmpk.2016.11.004_bib11","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJM200202143460721","article-title":"Cerivastatin and reports of fatal rhabdomyolysis","volume":"346","author":"Staffa","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.dmpk.2016.11.004_bib12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1124\/jpet.104.068536","volume":"311","author":"Shitara","year":"2004","journal-title":"J\u00a0Pharmacol Exp Ther"},{"year":"2012","series-title":"Guidance for Industry: drug interaction studies \u2013 study design, data analysis, implications for dosing, and labeling recommendation","author":"Center for Drug Evaluation and Research (CDER)","key":"10.1016\/j.dmpk.2016.11.004_bib13"},{"year":"2012","series-title":"Guideline on the investigation drug-drug interactions","author":"Committee for Medicinal Products for Human Use (CHMP)","key":"10.1016\/j.dmpk.2016.11.004_bib14"},{"key":"10.1016\/j.dmpk.2016.11.004_bib15","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1517\/17425255.2010.497487","article-title":"Rationalization and prediction of in\u00a0vivo metabolite exposures: the role of metabolite kinetics, clearance predictions and in\u00a0vitro parameters","volume":"6","author":"Lutz","year":"2010","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.dmpk.2016.11.004_bib16","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1124\/dmd.111.042200","article-title":"Prediction of relative in\u00a0vivo metabolite exposure from in\u00a0vitro data using two model drugs: dextromethorphan and omeprazole","volume":"40","author":"Lutz","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2016.11.004_bib17","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1124\/dmd.115.065920","article-title":"Physiologically based pharmacokinetic (PBPK) modeling and simulation approaches: a systematic review of published models, applications, and model verification","volume":"43","author":"Sager","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2016.11.004_bib18","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1021\/tx800491e","article-title":"Qualitative analysis of the role of metabolites in inhibitory drug-drug interactions: literature evalution based on the metabolism and transport drug interaction database","volume":"22","author":"Isoherranen","year":"2009","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.dmpk.2016.11.004_bib19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/clpt.2010.252","article-title":"Are circulating metabolites important in drug-drug interactions?: Quantitative analysis of risk prediction and inhibitory potency","volume":"89","author":"Yeung","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2016.11.004_bib20","doi-asserted-by":"crossref","first-page":"42","DOI":"10.2165\/00003088-199121010-00004","article-title":"Clinical pharmacokinetics in patients with liver disease","volume":"21","author":"McLean","year":"1991","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.dmpk.2016.11.004_bib21","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1053\/jhep.2001.29306","article-title":"Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts","volume":"34","author":"Chalasani","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.dmpk.2016.11.004_bib22","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3109\/00498258109045848","article-title":"Biotransformation of [14C]midazolam in the rat in\u00a0vitro and in\u00a0vivo","volume":"11","author":"Woo","year":"1981","journal-title":"Xenobiotica"},{"key":"10.1016\/j.dmpk.2016.11.004_bib23","doi-asserted-by":"crossref","first-page":"51S","DOI":"10.1111\/j.1365-2125.1983.tb02271.x","article-title":"Relationship between plasma concentration and effect of midazolam after oral and intravenous administration","volume":"16","author":"Crevoisier","year":"1983","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2016.11.004_bib24","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/bja\/89.3.428","article-title":"Contribution of midazolam and its 1-hydroxy metabolite to preoperative sedation in children: a pharmacokinetic-pharmacodynamic analysis","volume":"89","author":"Johnson","year":"2002","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.dmpk.2016.11.004_bib25","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/clpt.1992.84","article-title":"Pharmacokinetic-pharmacodynamic modelling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers","volume":"51","author":"Mandema","year":"1992","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2016.11.004_bib26","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S0022-3565(24)38237-0","article-title":"Characterization of the pharmacodynamic interaction between parent drug and active metabolite in\u00a0vivo: midazolam and alpha-OH-midazolam","volume":"289","author":"Tuk","year":"1999","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.dmpk.2016.11.004_bib27","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1124\/dmd.30.10.1059","article-title":"Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in rats, dogs, and monkeys","volume":"30","author":"Balani","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2016.11.004_bib28","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1006\/faat.1994.1042","article-title":"A\u00a013-week toxicologic and pathologic evaluation of prolonged cytochromes P450 inhibition by 1-aminobenzotriazole in male rats","volume":"22","author":"Meschter","year":"1994","journal-title":"Fundam Appl Toxicol"},{"key":"10.1016\/j.dmpk.2016.11.004_bib29","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/bdd.2000","article-title":"In\u00a0vitro and in\u00a0vivo characterization of CYP inhibition by 1-aminobenzotriazole in rats","volume":"37","author":"Parrish","year":"2016","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.dmpk.2016.11.004_bib30","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/jps.20538","article-title":"In\u00a0vivo use of the P450 inactivator 1-aminobenzotriazole in the rat: varied dosing route to elucidate gut and liver contributions to first-pass and systemic clearance","volume":"95","author":"Strelevitz","year":"2006","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.dmpk.2016.11.004_bib31","first-page":"246","article-title":"Effects of indole-3-carbinol and phenethyl isothiocyanate on bile and pancreatic juice excretion in rats","volume":"59","author":"Ishibashi","year":"2012","journal-title":"J\u00a0Med Invest"},{"key":"10.1016\/j.dmpk.2016.11.004_bib32","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/aps.2013.192","article-title":"Excretion of [3H]triptolide and its metabolites in rats after oral administration","volume":"35","author":"Liu","year":"2014","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.dmpk.2016.11.004_bib33","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1248\/bpb.25.1494","article-title":"A\u00a0novel method for preparation of animal models of liver damage: liver trageting of carbon tetrachloride in rats","volume":"25","author":"Mukai","year":"2002","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.dmpk.2016.11.004_bib34","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1248\/bpb.27.595","article-title":"Pharmacokinetics of phenol red in rat models of liver damage prepared by liver targeting of carbon tetracholoride","volume":"27","author":"Mukai","year":"2004","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.dmpk.2016.11.004_bib35","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1248\/bpb1978.6.595","article-title":"A\u00a0nonlinear least squares program based on differential equations, MULTI (RUNGE), for microcomputers","volume":"6","author":"Yamaoka","year":"1983","journal-title":"J\u00a0Pharmacobiodyn"},{"key":"10.1016\/j.dmpk.2016.11.004_bib36","first-page":"117","article-title":"The effects of felodipine on the pharmacokinetics of diazepam","volume":"30","author":"Meyer","year":"1992","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"10.1016\/j.dmpk.2016.11.004_bib37","doi-asserted-by":"crossref","first-page":"168","DOI":"10.2133\/dmpk.20.168","article-title":"Prediction of theophylline clearance in CCl4-treated rats using in\u00a0vivo CYP1A2 and CYP3A2 contents assessed with the PKCYP test","volume":"20","author":"Kose","year":"2005","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.dmpk.2016.11.004_bib38","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/S0022-3565(24)29211-9","article-title":"Midazolam is a phenobarbital \u2013like cytochrome p450 inducer in rats","volume":"299","author":"Hoen","year":"2001","journal-title":"J\u00a0Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2016.11.004_bib39","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3109\/00498259209053106","article-title":"Cytochromes P-450 in rats: structures, functions, properties and relevant human forms","volume":"22","author":"Soucek","year":"1992","journal-title":"Xenobiotica"},{"key":"10.1016\/j.dmpk.2016.11.004_bib40","doi-asserted-by":"crossref","first-page":"426","DOI":"10.2165\/00003088-197601060-00003","article-title":"Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure","volume":"1","author":"Drayer","year":"1976","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.dmpk.2016.11.004_bib41","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1677\/joe.0.0750305","article-title":"A\u00a0monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity","volume":"75","author":"Jordan","year":"1977","journal-title":"J\u00a0Endocrinol"},{"key":"10.1016\/j.dmpk.2016.11.004_bib42","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1093\/jnci\/djg108","article-title":"Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine","volume":"95","author":"Steams","year":"2003","journal-title":"J\u00a0Natl Cancer Inst"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436716301021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436716301021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:54:15Z","timestamp":1761162855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436716301021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S1347436716301021"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2016.11.004","relation":{},"ISSN":["1347-4367"],"issn-type":[{"type":"print","value":"1347-4367"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increase in the systemic exposure of primary metabolites of Midazolam in rat arising from CYP inhibition or hepatic dysfunction","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2016.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}